21 March 2023
EMA/102784/2003
EMEA/H/C/001236

Public statement

Lamivudine / Zidovudine Teva (lamivudine / zidovudine)

Withdrawal of the marketing authorisation in the European Union

On 9 March 2023, the European Commission withdrew the marketing authorisation for Lamivudine / Zidovudine Teva (lamivudine / zidovudine) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Teva B.V., which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Lamivudine / Zidovudine Teva was granted marketing authorisation in the EU on 28 February 2011 for treatment of HIV infection. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2015. The product had not been marketed in the EU since 2021.

Lamivudine / Zidovudine Teva is a generic medicine of Combivir.

The European Public Assessment Report (EPAR) for Lamivudine / Zidovudine Teva will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union